Breaking Finance News

A report released today by Zacks Investment Research about TrovaGene Inc (NASDAQ:TROV) bumps the target price to $5.25

Zacks Investment Research raised the target price of TrovaGene Inc (NASDAQ:TROV) to $5.25 reporting a possible upside of 0.10%.

Yesterday TrovaGene Inc (NASDAQ:TROV) traded -2.11% lower at $4.76. TrovaGene Inc’s 50-day average is $5.22 and its two hundred day average is $5.03. With the last close down -7.46% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 286,022 shares of TROV changing hands under the typical 289,822

Performance Chart

TrovaGene Inc (NASDAQ:TROV)

With a total market value of $0, TrovaGene Inc has with a one year low of $2.85 and a one year high of $7.22 .

In addition to Zacks Investment Research reporting its target price, a total of 5 firms have issued a report on the stock. The consensus target price is $6.30 with 0 equity analysts rating the company a strong buy, one equity analyst rating the company a buy, four equity analysts rating the company a hold, zero brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On TrovaGene Inc (NASDAQ:TROV)

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.